Peter
Clemmensen
Publicacións nas que colabora con Peter Clemmensen (3)
2021
-
Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol
Journal of the American College of Cardiology, Vol. 78, Núm. 5, pp. 421-433
2019
-
Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial
The Lancet Diabetes and Endocrinology, Vol. 7, Núm. 8, pp. 618-628
2018
-
Alirocumab and cardiovascular outcomes after acute coronary syndrome
New England Journal of Medicine, Vol. 379, Núm. 22, pp. 2097-2107